Latest Content

In November 2025, the FDA issued multiple oncology approvals that expanded treatment access for patients with breast, lung, blood and solid tumor cancers.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

I found purpose again after my myeloma diagnosis when I returned to teaching and shared my work, moments that reminded me I could still grow and reconnect.

I explain how the words caregiver and incurable shaped my wife’s cancer journey and why I believe more hopeful language better reflects our experience.

Cindy and Katie share how finding a friend who understood the caregiving journey made the experience less isolating and helped them navigate loss and hope.

Although most patients with localized kidney cancer have high cancer-specific survival, surveys show a gap between doctor and patient perceptions of cure.

CURE recently sat down with an expert to discuss crucial information for patients with gastrointestinal stromal tumors, or GISTs.

Among young patients, clinical trial results have shown that Pedmark is associated with a reduction in chemotherapy-induced ear damage.

An expert explained what patients newly diagnosed with gastrointestinal stromal tumors need to know.

Feeling like others have it worse can dismiss the real challenges of follicular lymphoma and leave patients without the support they need.

Cell therapies, which have made waves in the treatment of blood cancer, are showing potential for solid tumors.